Holiday Season Sale: Black Friday & Cyber Monday Deals by Xencelabs
The holiday season brings endless inspiration. Turn your creative thoughts into reality with state-of-the-art and innovative Pen Tablets that help create intricate digital drawings and designs. Act now to get our Pen Tablets, Quick Keys, and other products at discounted prices.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
PORTLAND, Ore., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Xencelabs Technologies Ltd. is offering this year’s biggest discounts to celebrate the beginning of the holiday season. These special discounted prices are applicable only on Black Friday and Cyber Monday and by purchasing products from Amazon and our e-stores.
We are dedicated to designing and creating digital drawing tools that facilitate artistic expression. Our goal is to build a community and collaborate with a wide variety of users in many creative fields at all levels of expertise.
Xencelabs has been created for all artists, designers, photographers, illustrators, VFX, and Media users to take back the natural editing and drawing experience and speed up their workflow.
Our online reviews from customers show us to be the new industry leader in the market, offering a strong competitive choice to users.
“I have worked on other pen tablets from competitors, I am confidently telling this is only the best one.”
“Both Xencelabs’ pen tablet and Quick Keys device are nice and easy to use. Shortcut keys that can be seen at a glance from the display and dial-type key operations allow smooth scaling of the screen and brushes, greatly improving work efficiency.”
Our customers’ passion drives Xencelabs innovations. We are happy to offer these special prices to all who want to bring their creativity to the next level, and this is the perfect opportunity to give the gift of better tools to the creative people in your life!
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
Sale details:
The Xencelabs' Global Black Friday promotional sale will be held from 18th November to 1st December 2022. (All promotional dates may vary depending on the region and their respective time zones)
Customers can get up to 30% discount on selected models open to all channels.
After Black Friday, we will also celebrate Cyber Monday with a limited-period offer from 28/11 - 4/12. (Promotion varied by respective time zones)
For more details relating to the Black Friday and Cyber Monday sales, visit our social media platforms:
Instagram: @Xencelabs / @Xencelabs_US / @Xencelabs.EMEA / @Xencelabs. SGMY
Twitter: @JapanXencelabs /@Xencelabs
The sale will be live on Amazon, Xencelabs' e-store and retail channel.
| Japan: | amzn.to/3RiaGYC |
| USA: | amzn.to/3jqwqD0 |
| Canda: | amzn.to/3ut2OLG |
| Mexico: | amzn.to/3jmX7bG |
| UK: | amzn.to/3v5oso9 |
| Germany: | amzn.to/3xikhYX |
| France: | amzn.to/37CFTEr |
| Italy: | amzn.to/3v6Zg0G |
| Spain: | amzn.to/37v1GOt |
| Netherlands: | amzn.to/38HrWG0 |
| Estore: | https://www.xencelabs.com/store |
Xencelabs – Together We Create
Xencelabs is a global company providing best-in-class digital and intuitive drawing solutions enabling creative professionals to expand their creativity and enhance productivity.
It was founded in 2019 by professionals with experience that spans various disciplines in industrial design, animation, VFX, illustration, software, engineering, IT, sales, marketing, government, and education. At Xencelabs, we are dedicated to exploring, innovating, designing, and developing the new generation of pen tablets. Our goal is to build communities and collaboration with other industry leaders. For further information, please contact
Xencelabs Technologies Limited.
Ian Sayers
Global Manager, Customer Engagement and Training
e: Ian.sayers@xencelabs.com
Pretty Leung
Senior Manager, Global Marketing
e: pretty.leung@xencelabs.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/6cc87bbf-b64e-4a3d-992f-611b83fcee8e
https://www.globenewswire.com/NewsRoom/AttachmentNg/92ba609d-36c7-421f-84a6-bd6796d2efc6
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Pharming Group announces the placement of €100 million convertible bonds due 202918.4.2024 15:04:30 CEST | Press release
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the "Shares"). The offer was fully subscribed. The New Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, Canada, Japan and South Africa. The New Bonds will have a principal amount of €100,000 each. The New Bonds will be issued at par and will carry a coupon of 4.50% per annum payable semi-annually in arrear in equal instalments on 25th April and 25th October of each y
Modelo Spiked Aguas Frescas Teams Up With Actress Francia Raisa and Community Changemaker Juixxe to Honor the Street Vendor Community18.4.2024 15:01:00 CEST | Press release
As Modelo Spiked Aguas Frescas expands to multiple markets, it celebrates street vendors who inspired the beverage by rewarding an aguas frescas street vendor with a custom-made cart and financial support to help grow their business CHICAGO, April 18, 2024 (GLOBE NEWSWIRE) -- Following a successful Las Vegas test launch, where Modelo Spiked Aguas Frescas was the #1 new Flavored Malt Beverage multipack and single serve*, Modelo is celebrating the expansion of Modelo Spiked Aguas Frescas to strong Modelo markets across the country by once again honoring the street vendor community that made traditional aguas frescas a beloved cultural staple. Partnering with actress Francia Raisa and Juixxe, a changemaker famous for uplifting the street vendor community, Modelo surprised the owner of Oxnard, CA-based Las Aguas 805, Salvador Gutierrez, with a new, custom-built street cart and a $5,000 cash gift to help him fuel the fiesta in his community with delicious aguas frescas for years to come. “A
Fluence Releases Annual Sustainability Report18.4.2024 15:00:00 CEST | Press release
Report outlines increased sustainability disclosures, including Fluence’s first Task Force on Climate-Related Financial Disclosures (TCFD) report ARLINGTON, Va., April 18, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a leading global provider of energy storage products and services, and optimization software for renewables and storage, issued its 2023 Sustainability Report (the “Report”) providing updates on the company’s sustainability strategy during the fiscal year ended September 30, 2023. The Report enhances and builds upon the sustainability disclosures from our inaugural sustainability report published in April 2023 and provides updates on Fluence’s sustainability strategy, including additional goals for 2024 and beyond. “Fluence operates with sustainability principles at our core and the urgency to address climate change imparts an urgency to our work. The speed at which we are moving towards our sustainability program commitments is a testament to
Decisions of Rapala VMC Corporation’s Annual General Meeting and Organising Meeting of the Board of Directors18.4.2024 15:00:00 CEST | Press release
RAPALA VMC CORPORATION, Decisions of general meeting, April 18, 2023 at 4:00 p.m. EET The Annual General Meeting (AGM) of Rapala VMC Corporation has on 18 April 2024 adopted the financial statement of the financial year 2023 and discharged the members of the Board of Directors and the CEO from liability for the financial year that ended on 31 December 2023. The AGM approved the remuneration report for governing bodies for the financial year 2023 and the remuneration policy for 2024-2027. The AGM approved the Board of Director’s proposal, according to which no dividend be paid based on the adopted balance sheet for the financial year 2023. The AGM approved that the Board of Directors consists of six members. Emmanuel Viellard, Julia Aubertin, Vesa Luhtanen and Alexander Rosenlew were re-elected as members of the Board of Directors and Pascal Lebard and Johan Berg were elected as new members. The AGM resolved that the annual fee paid to each Board member is EUR 25,000 and EUR 70,000 to t
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care18.4.2024 14:45:00 CEST | Press release
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers. Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's